Clinical Trial: A Phase 1 Study to Evaluate the Safety and Immunogenicity of GC4006A in Healthy Adults

U.S., July 28 -- ClinicalTrials.gov registry received information related to the study (NCT07728396) titled 'A Phase 1 Study to Evaluate the Safety and Immunogenicity of GC4006A in Healthy Adults' on July 15.

Brief Summary: A Phase 1, Randomized, Double-blind, Dose-Escalation, Placebo-Controlled, Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of the COVID-19 Preventive Vaccine 'GC4006A' in Healthy Adults Aged 19 to 64 Years

Study Start Date: Jan. 28

Study Type: INTERVENTIONAL

Condition: COVID - 19

Intervention: BIOLOGICAL: GC4006A

administered as a single dose via Intramuscular injection.

DRUG: Normal Saline

Matching placebo administered as a single dose via Intramuscular injection.

Recruitment Status: ACTIV...